

Volume 37 1974

Psycho— pharmacologia

Managing Editors

H. Barry III J. O. Cole M. Hamilton E. Jacobsen R. W. Russell

Editorial Board

H. Barry III, Pittsburgh D. Bovet, Sassari J. O. Cole, Boston J. Delay, Paris
J. Elkes, Baltimore M. Hamilton, Leeds H. Isbell, Lexington E. Jacobsen, København
M. E. Jarvik, Los Angeles S. S. Kety, Boston C. Kornetsky, Boston
R. W. Russell, Bedford Park M. Shepherd, London Hannah Steinberg, London
E. Strömgen, Risskov A. Wikler, Lexington

Supporting Editors

M. Adler, Philadelphia N.-E. Andén, Göteborg J. Angst, Zürich J. B. Appel, Columbia, SC
S. Barondes, La Jolla A. M. Barrett, Leeds H. Blaschko, Oxford D. Booth, Birmingham
H. Brill, New York P. Carlton, New Brunswick C. K. Connors, Boston P. B. Dews, Boston
A. DiMascio, Boston E. Domino, Ann Arbor J. C. Eccles, Buffalo
U. S. von Euler, Stockholm A. Fessard, Paris M. Fink, New York
S. Fisher, Boston R. Fog, Roskilde S. Garattini, Milano S. Gershon, New York
S. C. Goldberg, Chevy Chase S. P. Grossman, Chicago L.-M. Gunne, Uppsala
H. Hanson, West Point J. Harvey, Iowa City H. E. Hill, Lexington
R. Hind, Cambridge H. Hippus, München L. E. Hollister, Palo Alto
O. Hornykiewicz, Toronto E. Hosoya, Tokyo R. P. Hullin, Leeds S. Irwin, Portland
J. Jaffe, Chicago W. Janke, Düsseldorf R. Jewett, Atlanta
R. T. Jones, San Francisco M. Jouvét, Lyon C. R. B. Joyce, Basel D. Joyce, Perpignan
M. Katz, Rockville, MD R. Kelleher, Boston K. F. Killam, Davis
G. Klerman, Boston N. S. Kline, Orangeburg M. H. Lader, London I. P. Lapin, Leningrad
L. Lasagna, Rochester V. G. Laties, Rochester A. Latz, Raanana, Israel
O. Lingjærde, Tromsø R. Lipman, Rockville A. Lubin, San Diego E. Marley, London
W. R. Martin, Lexington J. L. McGaugh, Irvine D. E. McMillan, Chapel Hill
N. Mello, Washington A. F. Mirsky, Boston C. Niemegeers, Beerse S. Norton, Kansas City
D. H. Overstreet, Bedford Park, S. Australia D. Overton, Philadelphia G. Pampiglione, London
P. Pichot, Paris R. W. Pickens, Minneapolis A. Randrup, Roskilde D. Richter, Epsom
K. Rickels, Philadelphia R. Rodnight, London J. M. Rose, Leeds R. T. Rubin, Los Angeles
J. Scheel-Krüger, Roskilde J. Schildkraut, Boston C. Schuster, Chicago R. Shader, Boston
C. Shagass, Philadelphia P. Silverman, Macclesfield, Ches. F. Sjöqvist, Stockholm
J. R. Smythies, Edinburgh F. Sulser, Nashville R. Taber, Bloomfield J. Tecce, Boston
T. Thompson, Minneapolis S. Udenfriend, Nutley, NJ H. Weil-Malherbe, Washington
A. Weissman, Groton, CT T. Yanagita, Kawasaki E. Zaimis, London O. Zangwill, Cambridge



Springer-Verlag
Berlin Heidelberg New York

The exclusive copyright for all languages and countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publishers.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Springer-Verlag Berlin Heidelberg New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, Wiesbaden

© by Springer-Verlag Berlin Heidelberg 1974

Contents

Agué, C.: Cardiovascular Variables, Skin Conductance and Time Estimation: Changes after the Administration of Small Doses of Nicotine	109
Atkinson, R. C., see Darley, C. F., <i>et al.</i>	139
Avni, J., see Reigle, T. G., <i>et al.</i>	1
Baldwin, B. A., see Dantzer, R.	169
Beaton, J. M., LeBlanc, A. E., Webster, C. D.: The Effects of <i>d</i> -Amphetamine on the Inter-Response Times of Rats and Guinea-Pigs on a Modified Sidman Discriminated Avoidance Schedule	199
Begleiter, H., Porjesz, B., Yerre-Grubstein, C.: Excitability Cycle of Somatosensory Evoked Potentials during Experimental Alcoholization and Withdrawal	15
Braude, M. C., see Stadnicki, S. W., <i>et al.</i>	225
Breese, G. R., see Cooper, B. R., <i>et al.</i>	235
Bridges, S. R., see Martin, W. R., <i>et al.</i>	189
Buchwald, W. F., see Martin, W. R., <i>et al.</i>	189
Buus Lassen, J.: Evidence for a Noradrenergic and Dopaminergic Mechanism in the Hyperactivity Produced by 4, α -Dimethyl-m-tyramine (H 77/77) in Rats	331
Carlier, E., Nowaczyk, T., Valatx, J. L., Juvancz, P.: Etude du sommeil du raton nouveau-né isolé de sa mère. Effets de l'alpha-methyl-Dopa. The Development of Sleep in Newborn Rats Separated from Its Mothers. Effects of α -Methyl-Dopa	205
Chesher, G. B., Jackson, D. M.: Anticonvulsant Effects of Cannabinoids in Mice: Drug Interactions within Cannabinoids and Cannabinoid Interactions with Phenytoin	255
Clark, D. L., see Jones, B. C., <i>et al.</i>	37
Cohen, M. J., Rickles, W. H., Jr.: Performance on a Verbal Learning Task by Subjects of Heavy Past Marijuana Usage	323
Colasanti, B. K., Craig, C. R., Hartman, E. R.: Differential Effects of Pen-tylenetetrazol on REM Sleep in Naive and Cobalt-Epileptic Rats	151
Colombel, M.-C., see Jacob, J. J., <i>et al.</i>	217
Consroe, P. F., see Jones, B. C., <i>et al.</i>	37
Cooper, B. R., Cott, J. M., Breese, G. R.: Effects of Catecholamine-Depleting Drugs and Amphetamine on Self-Stimulation of Brain following Various 6-Hydroxydopamine Treatments	235
Cott, J. M., see Cooper, B. R., <i>et al.</i>	235
Craig, C. R., see Colasanti, B. K., <i>et al.</i>	151
Cytawa, J., see Trojnar, W., <i>et al.</i>	359
Dantzer, R., Baldwin, B. A.: Effects of Chlordiazepoxide on Heart Rate and Behavioural Suppression in Pigs Subjected to Operant Conditioning Procedures	169
Darley, C. F., Tinklenberg, J. R., Roth, W. T., Atkinson, R. C.: The Nature of Storage Deficits and State-Dependent Retrieval under Marijuana	139
Diaz, J., Ellison, G., Masuoka, D.: Opposed Behavioral Syndromes in Rats with Partial and More Complete Central Serotonergic Lesions Made with 5,6-Dihydroxytryptamine	67
Dick, E. G., see Naylor, G. J., <i>et al.</i>	81
Dick, D. A. T., see Naylor, G. J., <i>et al.</i>	81
Dunner, D. L., Meltzer, H. L., Fieve, R. R.: Cerebrospinal Fluid Rubidium Metabolism in Depression	7

Ellison, G., see Diaz, J., <i>et al.</i>	67
Engel, J., Strömbom, U., Svensson, T. H., Waldeck, B.: Suppression by α -Methyltyrosine of Ethanol-Induced Locomotor Stimulation: Partial Reversal by L-Dopa	275
Fann, W. E., Lake, C. R., Gerber, C. J., McKenzie, G. M.: Cholinergic Suppression of Tardive Dyskinesia	101
Ferraro, D. P., Grilly, D. M.: Effects of Chronic Exposure to Δ^9 -Tetrahydrocannabinol on Delayed Matching-to-Sample in Chimpanzees	127
Fieve, R. R., see Dunner, D. L., <i>et al.</i>	7
File, S. E., Pope, J. H.: The Action of Chlorpromazine on Exploration in Pairs of Rats	249
Frankel, D., Khanna, J. M., Kalant, H., LeBlanc, A. E.: Effect of Acute and Chronic Ethanol Administration on Serotonin Turnover in Rat Brain	91
Frydrychowski, A., see Trojnar, W., <i>et al.</i>	359
Gerber, C. J., see Fann, W. E., <i>et al.</i>	101
Gerlach, J., Nielsen, M., Randrup, A.: Effect of Desipramine on Rat Cortex Slices Incubated with ^3H -Dopamine	341
Gillin, J. C., see Post, R. M., <i>et al.</i>	59
Gittelman-Klein, R., see Saraf, K. R., <i>et al.</i>	265
Goodwin, F. K., see Post, R. M., <i>et al.</i>	59
Grilly, D. M., see Ferraro, D. P.	127
Groff, S., see Saraf, K. R., <i>et al.</i>	265
Haig, J. R., Schroeder, C. S., Schroeder, S. R.: Effects of Methylphenidate on Hyperactive Children's Sleep	185
Hansen, C. E., Larsen, N.-E.: Perphenazine Concentrations in Human Whole Blood. A Pilot Study during Anti-Psychotic Therapy Using Different Administration Forms	31
Harris, R. T., Waters, W., McLendon, D.: Evaluation of Reinforcing Capability of Delta-9-Tetrahydrocannabinol in Rhesus Monkeys	23
Hartman, E. R., see Colasanti, B. K., <i>et al.</i>	151
Herman, Z. S., see Janiec, W., <i>et al.</i>	351
Jackson, D. M., see Chesher, G. B.	255
Jacob, J. J., Tremblay, E. C., Colombel, M.-C.: Facilitation de réactions nociceptives par la naloxone chez la souris et chez le rat. Enhancement of Nociceptive Reactions by Naloxone in Mice and Rats	217
James, L., see Wise, R. A.	179
Janiec, W., Korczak-Dziuba, K., Herman, Z. S.: Effect of Phenothiazine Neuroleptic Drugs and Tricyclic Antidepressants on Phosphodiesterase Activity in Rat Cerebral Cortex	351
Jones, B. C., Clark, D. L., Consroe, P. F., Smith, H. J.: Effects of $(-)\Delta^9$ -trans-Tetrahydrocannabinol on Social Behavior of Squirrel Monkey Dyads in a Water Competition Situation	37
Juvancz, P., see Carlier, E., <i>et al.</i>	205
Kalant, H., see Frankel, D., <i>et al.</i>	91
Khanna, J. M., see Frankel, D., <i>et al.</i>	91
Klein, D. F., see Saraf, K. R., <i>et al.</i>	265
Korczak-Dziuba, K., see Janiec, W., <i>et al.</i>	351
Koyuncuoğlu, H.: The Effects of Chronic Reserpine and Nialamide Treatment on the Free Amino Acid Levels of Rat Brain	87
Lake, C. R., see Fann, W. E., <i>et al.</i>	101
Lal, H., see Wauquier, A., <i>et al.</i>	303
Landauer, A. A., Pocock, D. A., Prott, F. W.: The Effect of Medazepam and Alcohol on Cognitive and Motor Skills Used in Car Driving	159
Larsen, N.-E., see Hansen, C. E.	31
LeBlanc, A. E., see Frankel, D., <i>et al.</i>	91

LeBlanc, A. E., see Beaton, J. M., <i>et al.</i>	199
Luszwaska, D., see Trojnar, W., <i>et al.</i>	359
Martin, W. R., Sloan, J. W., Buchwald, W. F., Bridges, S. R.: The Demonstration of Tryptamine in Regional Perfusates of the Dog Brain	189
Masuoka, D., see Diaz, J., <i>et al.</i>	67
McKenzie, G. M., see Fann, W. E., <i>et al.</i>	101
McLendon, D., see Harris, R. T., <i>et al.</i>	23
McNair, D. M.: Self-Evaluations of Antidepressants	281
Meisch, R. A., Thompson, T.: Rapid Establishment of Ethanol as a Reinforcer for Rats	311
Meltzer, H. L., see Dunner, D. L., <i>et al.</i>	7
Moody, J. P., see Naylor, G. J., <i>et al.</i>	81
Mormont, C.: Evaluation des effets psychologiques du Noveril simple et du Noveril TR. Rating of Psychological Effects Induced by "Ordinary" Noveril and Time-Released Noveril	365
Naylor, G. J., Dick, D. A. T., Dick, E. G., Moody, J. P.: Lithium Therapy and Erythrocyte Membrane Cation Carrier	81
Nielsen, M., see Gerlach, J., <i>et al.</i>	341
Niemegeers, C. J. E., see Wauquier, A., <i>et al.</i>	303
Nowaczyk, T., see Carlier, E., <i>et al.</i>	205
Platz, P. A., see Reigle, T. G., <i>et al.</i>	1
Plotnikoff, N. P., see Reigle, T. G., <i>et al.</i>	1
Pocock, D. A., see Landauer, A. A., <i>et al.</i>	159
Van der Poel, A. M.: The Effect of Some Cholinolytic Drugs on a Number of Behavioural Parameters Measured in the T-Maze Alternation Test: Dose-Response Relationships	45
Pope, J. H., see File, S. E.	249
Porjesz, B., see Begleiter, H., <i>et al.</i>	15
Post, R. M., Gillin, J. C., Wyatt, R. J., Goodwin, F. K.: The Effect of Orally Administered Cocaine on Sleep of Depressed Patients	59
Prott, F. W., see Landauer, A. A., <i>et al.</i>	159
Randrup, A., see Gerlach, J., <i>et al.</i>	341
Reigle, T. G., Avni, J., Platz, P. A., Schildkraut, J. J., Plotnikoff, N. P.: Norepinephrine Metabolism in the Rat Brain Following Acute and Chronic Administration of Thyrotropin Releasing Hormone	1
Rickles, W. H., Jr., see Cohen, M. J.	323
Roth, W. T., see Darley, C. F., <i>et al.</i>	139
Rosenkrantz, H., see Stadnicki, S. W., <i>et al.</i>	225
Saraf, K. R., Klein, D. F., Gittelman-Klein, R., Groff, S.: Imipramine Side Effects in Children	265
Schaeppi, U., see Stadnicki, S. W., <i>et al.</i>	225
Schildkraut, J. J., see Reigle, T. G., <i>et al.</i>	1
Schroeder, C. S., see Haig, J. R., <i>et al.</i>	185
Schroeder, S. R., see Haig, J. R., <i>et al.</i>	185
Sloan, J. W., see Martin, W. R., <i>et al.</i>	189
Smith, H. J., see Jones, B. C., <i>et al.</i>	37
Stadnicki, S. W., Schaeppi, U., Rosenkrantz, H., Braude, M. C.: Crude Marihuana Extract: EEG and Behavioral Effects of Chronic Oral Administration in Rhesus Monkeys	225
Svensson, T. H., see Engel, J., <i>et al.</i>	275
Strömbom, U., see Engel, J., <i>et al.</i>	275
Thompson, T., see Meisch, R. A.	311
Tinklenberg, J. R., see Darley, C. F., <i>et al.</i>	139
Tremblay, E. C., see Jacob, J. J., <i>et al.</i>	217
Trojnar, W., Cytawa, J., Frydrychowski, A., Luszwaska, D.: Intragastric Self-Administration of Morphine as a Measure of Addiction	359

VI

Contents

Valatx, J. L., see Carlier, E., <i>et al.</i>	205
Waldeck, B., see Engel, J., <i>et al.</i>	275
Waters, W., see Harris, R. T., <i>et al.</i>	23
Wauquier, A., Niemegeers, C. J. E., Lal, H.: Differential Antagonism by Naloxone of Inhibitory Effects of Haloperidol and Morphine on Brain Self- Stimulation	303
Webster, C. D., see Beaton, J. M., <i>et al.</i>	199
Wise, R. A., James, L.: Rat Ethanol Intake: Suppression by Intracranial Surgery and Facilitation by Intracranial Stimulation	179
Wyatt, R. J., see Post, R. M., <i>et al.</i>	59
Yerre-Grubstein, C., see Begleiter, H., <i>et al.</i>	15

Indexed in Current Contents

Subject Index

A

Acquisition 311
Addiction 359
Alcohol-drug interaction 159
Alcoholics 15
Alcoholism, animal models of 179
Alternation 45
Ambivalent behavior 45
Amino acids, free 87
Amphetamine 235
d-Amphetamine 199
Anticonvulsant 255
Antidepressants 1, 281, 365
—, tricyclic 351
Anti-psychotic-therapy 31
Anxiety, chronic 671
Artificial feeding 205
Autism 67
Automobile driving 159

B

Behavioral conflict 45
Biogenic amines 1
Blood pressure 265
Bovet-Gatti profiles 199
Brain 87
—, dopamine 235
—, hyperexcitability 15
—, norepinephrine 235
—, self-stimulation 303
—, serotonin-turnover 91

C

Cannabidiol 255
Cannabinol 255
Cataplexy 303
Catatonia 303
Catecholamines 1
Cerebrospinal fluid 7
Children 265
—, hyperactive 185
Chimpanzees 127
Chlordiazepoxide 169
Chlorpromazine 249
Cholinergic 101
Cholinolytic-dose response relations 45
Chronic doses 127, 225
Clinical trials 281
Cobalt epilepsy 151
Cocaine 59, 341
Cognitive tests 159
Competition 37
Conflict behavior 169
Cortex slices 341
Cortisol 81
Cyclic 3-, 5-AMP 351

D

Delayed matching-to-sample 127
Depression 1, 59, 281
Desipramine 341
Dibenzepine 365
5,6-Dihydroxytryptamine 67
Dogs 189
Dopamine 1, 235, 331, 341
Dopaminergic 101
 α -*m*-Dopa 205
L-Dopa 275
Dreaming 59
Drug interactions 255
Drug self-administration 23
Dyskinesia, tardive 101

E

EEG 59, 151, 225
Erythrocyte 81
Ethanol 91, 275
—, concentration 311
—, intake 179
—, preference 179
—, reinforcement 311
Exaggerated recovery 67
Exploration 249

F

FLA 63 341
Forearm blood flow 109

G

Gas chromatography 31
Guinea pigs 199

H

H 77/77 331
Hallucinogens 189
Haloperidol 303
Heart rate 109
High dosages, imipramine 265
Hotplate 217
5-HT lesions 67
Human pharmacokinetics 31
Human subjects 7, 15, 31, 59, 81, 101, 109, 139, 159, 185, 265, 281, 323, 365, 371
6 Hydroxydopamine 235
Hyperactive children 185
Hypothalamic stimulation 179

I

Imipramine hydrochloride 265
Instrumental conditioning 359
Intoxication 15
Intragastric reinforcement 359
Intravenous route 23

VIII

Subject Index

L

- Learning-state-dependent 139
- Lithium 81
- Locomotor activity 275
- Long-acting drug 365

M

- Manic depressive psychosis 81
- Marihuana 127, 139, 225, 323
- Medazepam 159
- Medial forebrain bundle 303
- Memory 127, 323
 - , storage 139
- Methylphenidate 185
- α -Methyl tyrosine 235, 275
- Mice 217, 255
- MMPI 365
- Monkeys, rhesus 23, 225
 - , squirrel 37
- Morphine 303, 359
- Motility 331
- Motor activity, general 249
- Motor skills 159

N

- N₂-K ATPase 81
- Naloxone 217, 303
- Neuroleptics 331
- Neurotransmission 189
- Nialamide 87
- Nicotine 109
- N-methyl-4-Piperidyl Methylethynyl-
Glycolate 45
- Nociceptive reactions 217
- Non-reinforcement 169
- Noradrenaline 331, 341
- Norepinephrine 1, 235

O

- Ontogenesis 205
- Ouabain sensitive K⁺ influx 81

P

- Paradoxical sleep 205
- Past usage, marihuana 323
- Pentylene-tetrazol 151
- Perphenazine 31
- Phenobarbitone 255
- Phenothiazine neuroleptics 351
- Phenytoin 255
- Phosphodiesterase 351
- Physostigmine 101
- Pigs 169
- Placebo 281
- Polydipsia, schedule-induced 311
- Ptoxis 303
- Pulse 265

Q

- Questionnaires 159
- 3-Quinuclidinyl benzilate 45

R

- Rating Scales 281, 365
- Rats 11, 45, 67, 87, 91, 151, 179, 199, 217, 235, 249, 303, 311, 331, 341, 351, 359
 - , newborn 205
- Rehearsal 139
- REM sleep 151
- Reserpine 87, 341
- Restoration 275
- Rubidium 7

S

- Safety, imipramine 265
- Self-administration 359
 - , drug 23
- Self-stimulation 235
- Serotonin 1, 91
- Skin conductance 109
 - , temperature 109
- Sleep 59, 185
- Smoking 109
- Social behavior 37
 - , interaction 249
- State dependency 323
- Stimulants 59
- Sudden death 265
- Supersensitivity 67
- Suppression 101, 275

T

- Tardive dyskinesia 101
- Δ^9 THC 23, 37, 127, 139, 225, 255
- Thymoleptics 331
- Thyrotropin releasing hormone 1
- Time estimation 109
- T-Maze 45
- Tolerance 91, 127, 225
- Tranquillizers 159
- Tricyclic antidepressants 351
- Tryptamine 189

U

- U-14624 235

V

- Validity 281
- Verbal learning 323

W

- Whole blood concentrations 31
- Withdrawal 15

Notes on Preparation of Illustrations

Selection of illustration material: In order to obtain the best results in reproduction, to avoid delays during production and hence unnecessary costs, we ask authors to note the following points when selecting and preparing illustration copy.

1. Half-tones (photographs, photomicrographs, X-rays, instrument traces etc.)

- Send only good, well-contrasted glossy prints of the original negative; prints should be trimmed at right angles; send contact copies of X-rays — if these are not available, the actual X-ray films.
- Mark or trim off marginal portions which are not required (at right angles, please).
- State scale of reduction, if any, with due allowance for the format of the printed page (print area).
- Group figures into whole-page plates; see that they match in the proposed scale of reduction.
- With X-rays, in particular, mark the significant portions on the back of the copy, or on a cover sheet.
- Enter inscriptions, marker lines etc. neatly and in the appropriate size, either on the photograph itself or on a cover sheet.

2. Line drawings

- State final size of illustration, with due allowance for print area.
- The ideal is for drawings to be twice the final size and executed in indelible black ink.

Important points to note: thickness of lines, size of inscriptions, size of measuring points, adequate spacing of shaded and dotted areas.





Words should be in upper and lower case characters (not block capitals).

Example showing the effect of reduction $\times \frac{1}{2}$.

ABCDEFGHIJKLMNOPQRSTUVWXYZ
abcdefghijklmnopqrstuvwxyzß
1234567890
(!:"'+=,x?%)

ABCDEFGHIJKLMNOPQRSTUVWXYZ
abcdefghijklmnopqrstuvwxyzß
1234567890
(!:"'+=,x?%)

Some more examples see overleaf



Examples showing the effect of reduction $\times 1/4$

Instructions to Authors

1. Papers will be published in **English, French or German.**
2. Authors should submit **manuscripts together with two copies.** The original illustration material (original drawings etc.) and two copies should be submitted together with the manuscript.
3. The text should be as **clear and concise** as possible. Both form and content of the paper should be carefully checked to exclude the need for corrections in proof. A charge will be made for changes introduced after the manuscript has been set in type.
4. **Manuscripts** should be typewritten, double-spaced, on one side of letter size paper and with wider margin on the left. The author should mark in the margin where figures and tables may be inserted. All pages should be numbered consecutively. Tables, footnotes and legends for illustrations should be typed (double-spaced) on separate pages. Use the metric system for text and figures.
5. The **first page** should bear:
the title; the name(s) of the author(s); the name of the laboratory where the work was carried out; a running title of not more than 67 typewriter strokes; footnotes to the title (marked by asterisks).
6. Each paper should be preceded by a brief **abstract** in English concerned with the methods used and with the experimental results which should be presented in such a way that it is possible for the reader to assess their significance. It should be as short as possible and should **not exceed 200 words.**
French and German articles should also have an **English translation of the title.**
7. Immediately following the abstract, some relevant **key words** should be supplied for subject indexing.
8. Articles dealing with **original investigations** should first state the problem concisely and arrange the material under Methods, Results, Discussion, References.
9. **Footnotes** should be kept to a minimum and numbered consecutively throughout the paper. Footnotes referring to the heading of the article are to be marked by asterisks.
10. The **bibliography** should include only work cited in the text. References should be listed alphabetically at the end of the paper as follows: *journal papers*—names and initials of all authors, full title, journal abbreviated in accordance with World Medical Periodicals, volume number, first and last page numbers, year in parentheses; *books*—names of authors, full title, edition, place, publisher, year. *Examples:*
Latz, A., Bain, G. T., Kornetsky, C.: Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. *Psychopharmacologia (Berl.)* **14**, 23—32 (1960).
Fisher, S., Cole, J. O., Rickels, K., Uhlenhuth, E. H.: Drug set interaction: The effect of expectation on drug response in outpatients. In: *Neuropsychopharmacology*. Bradley, P. B., Flugle, F., and Hoch, P., Eds., Vol. 3, pp. 149—156. Amsterdam: Elsevier 1964.
Several publications by the same author or group of authors should be listed in chronological order; those that appear in the same year should be distinguished by the suffixes a, b, c etc. Citations in the text should be given in parentheses, e.g. (Beckman, 1958; Brown, 1963), except when the author's name is part of a sentence, e.g. "Man (1966) reported that . . ." When a paper with more than two authors is cited, all authors are named the first time, but subsequently only the first author, e.g. (Miller *et al.*, 1963).
11. Figures should be separated from the text and numbered. They should be restricted to a minimum. Descriptions in captions should not be expanded in the text, nor should the same data be given in both graph and table form. Coloured or previously published illustrations are not usually accepted. Original drawings and graphs should be drawn in Indian ink with lines of uniform thickness. Where possible, **figures should be grouped**, bearing in mind maximum display area is 108×177 mm ($4\frac{1}{4} \times 7''$). In general it should be assumed that the same degree of reduction will apply to all figures in the same paper. Inscriptions should allow for any reduction in scale—a capital letter should be about 1.8 mm high in the final version. If figures have to be redrawn for the block-maker, this may cause considerable delay in publication. Photographs should be sharp, well-contrasted glossy prints at right angles. Authors should mark them with Letraset (Instant Lettering).

How many hours do you spend just looking for the articles you want to read?

- ☐ 1 hr. per week
☐ 2 hrs. per week
☐ 3 hrs. per week

That's how many hours ASCA® will save you.

If you're typical of most researchers, it's been shown that you spend up to one-fourth of your time just trying to keep abreast of advances in your field. And that includes many hours just looking for the articles. One, two, maybe three hours that ASCA can save you every week. For only \$3 a week.

ASCA (*Automatic Subject Citation Alert*) saves your time by finding these important articles for you. You simply tell us what subjects interest you. What authors. What research. And we'll prepare a personal computer profile for you which reflects your exact reading interests no matter how narrow or wide ranging they

may be. Then each week, ASCA's computer compares this profile with the articles in 3,500 leading scientific and technical journals and prints out a custom-tailored list telling you which articles to read and exactly where to find them.

But you'll never know how much time ASCA can save you until you try it. Give an ASCA information specialist a call (215-923-3300) and ask about our 13-week, \$39 introductory offer. Or fill in and mail the coupon below. Then think about what you're going to do with all the time you'll save.

©1974 ISI

isi®

Institute for Scientific Information

325 Chestnut Street, Philadelphia, Pennsylvania 19106

SV-394

☐ I'd like to take advantage of your introductory offer and try ASCA® for 13 weeks at \$39. Please contact me. (Trial offer is limited to residents of the continental United States, Europe, and Mexico.)

Name _____

Position _____

Organization _____

Address _____

City _____

State _____

Zip _____

Country _____

Telephone _____

Extension _____

Responsible for advertisement: L. Siegel, D-1000 Berlin 15, Kurfürstendamm 237

Telephone: (030) 8821031, Telex: 01-85411

Springer-Verlag, Berlin · Heidelberg · New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, D-6200 Wiesbaden

© by Springer-Verlag, Berlin · Heidelberg 1974

